Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net ...
Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with ...
LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results